ARTHEx Biotech
PrivateLast Round
Series B
Sep 17, 2025
Total Funding Raised
$95M
Company Overview
ARTHEx Biotech operates in Healthcare & Life Sciences and is based in Valencia. Its latest recorded funding round was a Series B round in September 2025.
ARTHEx Biotech is a biotechnology company that develops targeted RNA medicines for rare genetic neuromuscular disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ARTHEx Biotech Comparables
Compare ARTHEx Biotech with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Novartis | 83% | |
| PepGen | 81% | |
| Juvena Therapeutics | 81% |
For institutional investors. Book with your work email.
ARTHEx Biotech Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 17, 2025 | ||||
| Series A | Jul 20, 2022 | ||||
| Seed | Jul 23, 2020 | ||||
| Seed | Jun 1, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ARTHEx Biotech Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Series B |
| Hadean Ventures | Series B |
| Center for Technological Development and Innovation | Seed, Series B |
| Invivo Partners | Seed, Series B |
| Columbus Venture Partners | Series B |
| European Union Funding Programmes | Series B |
| Bpifrance | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Monthly visitors increased 117% MoM.
- May 17, 2026
Monthly visitors increased 67% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresNov 4, 2026
Arthex Biotech hires Dr. Freitag, who brings more than two decades of biopharmaceutical experience as the company builds clinical and regulatory capabilities for ATX-01 in Spain.
- hiresNov 4, 2026
Arthex Biotech appoints Christian Freitag, M.D., as Chief Medical Officer to lead clinical development and medical strategy for its RNA-based therapeutics in Spain on Nov 4th '26.
For institutional investors. Book with your work email.
ARTHEx Biotech Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ARTHEx Biotech's valuation, stock price, and market status.
Is ARTHEx Biotech a public or private company?
ARTHEx Biotech is a private company.
What is the current stock price of ARTHEx Biotech?
ARTHEx Biotech is a private company, so its shares have no public market price. Caplight tracks ARTHEx Biotech's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ARTHEx Biotech worth (valuation)?
Valuation information for ARTHEx Biotech is not publicly available.
Can I buy ARTHEx Biotech stock?
ARTHEx Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ARTHEx Biotech's last funding round?
ARTHEx Biotech's most recent funding round was Series B on September 17, 2025.
Who are the main investors in ARTHEx Biotech?
Key investors in ARTHEx Biotech include Invivo Partners, Bpifrance, AdBio partners.
Will ARTHEx Biotech IPO soon?
No public IPO plans have been announced for ARTHEx Biotech.
How can I track ARTHEx Biotech secondary market activity?
Caplight tracks bids, offers, and trades in ARTHEx Biotech's shares on secondary markets.